Display options
Cite
Gorbunov NV, Sharma P. Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome. Antioxidants (Basel). 2015;4(1):134-52doi: 10.3390/antiox4010134.
Gorbunov, N. V., & Sharma, P. (2015). Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome. Antioxidants (Basel, Switzerland), 4(1), 134-52. https://doi.org/10.3390/antiox4010134
Gorbunov, Nikolai V, and Sharma, Pushpa. "Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome." Antioxidants (Basel, Switzerland) vol. 4,1 (2015): 134-52. doi: https://doi.org/10.3390/antiox4010134
Gorbunov NV, Sharma P. Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome. Antioxidants (Basel). 2015 Feb 27;4(1):134-52. doi: 10.3390/antiox4010134. PMID: 26785342; PMCID: PMC4665569.
Copy Download .nbib Format: NLM
Share it on

Antioxidants (Basel). 2015 Feb 27;4(1):134-52. doi: 10.3390/antiox4010134.

Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome.

Antioxidants (Basel, Switzerland)

Nikolai V Gorbunov, Pushpa Sharma

Affiliations

  1. Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. [email protected].
  2. Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

PMID: 26785342 PMCID: PMC4665569 DOI: 10.3390/antiox4010134

Abstract

The biological effects of high-dose total body ionizing irradiation [(thereafter, irradiation (IR)] are attributed to primary oxidative breakage of biomolecule targets, mitotic, apoptotic and necrotic cell death in the dose-limiting tissues, clastogenic and epigenetic effects, and cascades of functional and reactive responses leading to radiation sickness defined as the acute radiation syndrome (ARS). The range of remaining and protracted injuries at any given radiation dose as well as the dynamics of post-IR alterations is tissue-specific. Therefore, functional integrity of the homeostatic tissue barriers may decline gradually within weeks in the post-IR period culminating with sepsis and failure of organs and systems. Multiple organ failure (MOF) leading to moribundity is a common sequela of the hemotapoietic form of ARS (hARS). Onset of MOF in hARS can be presented as "two-hit phenomenon" where the "first hit" is the underlying consequences of the IR-induced radiolysis in cells and biofluids, non-septic inflammation, metabolic up-regulation of pro-oxidative metabolic reactions, suppression of the radiosensitive hematopoietic and lymphoid tissues and the damage to gut mucosa and vascular endothelium. While the "second hit" derives from bacterial translocation and spread of the bacterial pathogens and inflammagens through the vascular system leading to septic inflammatory, metabolic responses and a cascade of redox pro-oxidative and adaptive reactions. This sequence of events can create a ground for development of prolonged metabolic, inflammatory, oxidative, nitrative, and carbonyl, electrophilic stress in crucial tissues and thus exacerbate the hARS outcomes. With this perspective, the redox mechanisms, which can mediate the IR-induced protracted oxidative post-translational modification of proteins, oxidation of lipids and carbohydrates and their countermeasures in hARS are subjects of the current review. Potential role of ubiquitous, radioresistant mesenchymal stromal cells in the protracted responses to IR and IR-related septicemia is also discussed.

Keywords: carbonylation; electrophilic stress; hematopoietic acute radiation syndrome; homeostatic tissue barriers; intracranial hemorrhage; ionizing radiation; nitration; non-targeted epigenetic and clastogenic effects; radiation-induced oxidation; vascular injury

References

  1. Radiat Res. 1999 Mar;151(3):270-7 - PubMed
  2. Radiat Res. 2000 Feb;153(2):196-200 - PubMed
  3. Radiat Res. 2000 Jul;154(1):73-86 - PubMed
  4. Ann N Y Acad Sci. 2000;899:44-60 - PubMed
  5. Cancer Res. 2001 May 15;61(10):3894-901 - PubMed
  6. Bull Acad Natl Med. 2000;184(8):1609-19; discussion 1619-20 - PubMed
  7. J Biol Chem. 2002 May 3;277(18):15400-6 - PubMed
  8. Free Radic Biol Med. 2002 May 1;32(9):790-6 - PubMed
  9. Free Radic Biol Med. 2002 Jul 15;33(2):201-9 - PubMed
  10. Mutat Res. 2003 Jan 28;522(1-2):45-56 - PubMed
  11. Free Radic Biol Med. 2003 Jul 1;35(1):68-77 - PubMed
  12. Oncogene. 2003 Sep 1;22(37):5813-27 - PubMed
  13. Radiat Res. 1958 Nov;9(5):498-501 - PubMed
  14. Mutat Res. 2003 Oct 29;531(1-2):5-23 - PubMed
  15. Radiat Res. 2004 Feb;161(2):143-52 - PubMed
  16. Curr Cancer Drug Targets. 2004 Feb;4(1):53-64 - PubMed
  17. Mil Med. 2004 Mar;169(3):194-7 - PubMed
  18. Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):311-22 - PubMed
  19. Biophys J. 2004 Sep;87(3):2022-34 - PubMed
  20. Biochem Biophys Res Commun. 2005 Aug 26;334(2):298-305 - PubMed
  21. Radiat Res. 2006 Apr;165(4):373-8 - PubMed
  22. Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17 - PubMed
  23. FEMS Immunol Med Microbiol. 2006 Jul;47(2):167-77 - PubMed
  24. Genetics. 1958 Sep;43(5):835-43 - PubMed
  25. Free Radic Biol Med. 2008 Feb 1;44(3):299-314 - PubMed
  26. J Biol Chem. 2008 Aug 8;283(32):21837-41 - PubMed
  27. Am J Physiol Cell Physiol. 2008 Oct;295(4):C849-68 - PubMed
  28. Mol Interv. 2008 Dec;8(6):294-302 - PubMed
  29. Curr Med Chem. 2009;16(2):130-43 - PubMed
  30. Semin Radiat Oncol. 2009 Apr;19(2):133-9 - PubMed
  31. Radiat Res. 2009 May;171(5):596-605 - PubMed
  32. J Pathol. 2009 Oct;219(2):242-52 - PubMed
  33. Antioxid Redox Signal. 2010 Mar;12(3):393-404 - PubMed
  34. J Exp Med. 1923 Nov 30;38(6):741-52 - PubMed
  35. J Exp Med. 1937 Nov 30;66(6):667-88 - PubMed
  36. Free Radic Biol Med. 2010 Jan 15;48(2):348-56 - PubMed
  37. Int J Radiat Biol. 2010 Jun;86(6):429-35 - PubMed
  38. Amino Acids. 2010 Nov;39(5):1131-7 - PubMed
  39. J Clin Invest. 2010 Jul;120(7):2528-36 - PubMed
  40. Intensive Care Med. 2010 Nov;36(11):1826-35 - PubMed
  41. Annu Rev Physiol. 2011;73:213-37 - PubMed
  42. Free Radic Biol Med. 2011 Jan 15;50(2):400-7 - PubMed
  43. Curr Mol Pharmacol. 2011 Jun;4(2):96-105 - PubMed
  44. Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1111-23 - PubMed
  45. PLoS One. 2011 Jan 05;6(1):e14486 - PubMed
  46. J Exp Med. 2011 Mar 14;208(3):417-20 - PubMed
  47. Oncogene. 2011 Nov 10;30(45):4601-8 - PubMed
  48. Mutat Res. 2011 Sep 1;714(1-2):113-25 - PubMed
  49. Chem Rev. 2011 Oct 12;111(10):5997-6021 - PubMed
  50. PLoS One. 2011;6(9):e25210 - PubMed
  51. Biochem Biophys Res Commun. 2011 Nov 4;414(4):795-800 - PubMed
  52. PLoS One. 2011;6(12):e27811 - PubMed
  53. In Vivo. 2012 Jan-Feb;26(1):9-18 - PubMed
  54. ACS Med Chem Lett. 2011 Nov 10;2(11):814-817 - PubMed
  55. Biochem J. 2012 Mar 15;442(3):453-64 - PubMed
  56. Blood. 2012 Apr 12;119(15):3629-37 - PubMed
  57. J Physiol Biochem. 2013 Mar;69(1):147-54 - PubMed
  58. Radiat Environ Biophys. 2013 Mar;52(1):5-16 - PubMed
  59. Mol Ther. 2013 Feb;21(2):423-32 - PubMed
  60. Adv Exp Med Biol. 2013;990:37-48 - PubMed
  61. Apoptosis. 2013 Jul;18(7):896-909 - PubMed
  62. Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1857-66 - PubMed
  63. Radiat Res. 2013 Jul;180(1):100-9 - PubMed
  64. Oxid Med Cell Longev. 2013;2013:186795 - PubMed
  65. Free Radic Biol Med. 2013 Dec;65:607-619 - PubMed
  66. Free Radic Biol Med. 2013 Dec;65:828-837 - PubMed
  67. Redox Biol. 2013 Jan 26;1:56-64 - PubMed
  68. Redox Biol. 2013 Feb 12;1:94-6 - PubMed
  69. Cancer Lett. 2015 Jan 1;356(1):34-42 - PubMed
  70. Antioxid Redox Signal. 2014 Jul 10;21(2):260-92 - PubMed
  71. EMBO J. 2014 May 2;33(9):994-1010 - PubMed
  72. Nat Rev Immunol. 2014 Mar;14(3):141-53 - PubMed
  73. Redox Biol. 2014 Jan 20;2:430-5 - PubMed
  74. Nat Commun. 2014 Mar 18;5:3494 - PubMed
  75. Oxid Med Cell Longev. 2014;2014:481392 - PubMed
  76. J Proteome Res. 2014 Jun 6;13(6):3065-74 - PubMed
  77. Redox Biol. 2014 Feb 28;2:832-46 - PubMed
  78. Oxid Med Cell Longev. 2014;2014:215858 - PubMed
  79. Haematol Blood Transfus. 1989;32:159-67 - PubMed
  80. Proteomes. 2014 Jun 25;2(3):291-302 - PubMed
  81. Biochem J. 1988 Oct 15;255(2):513-22 - PubMed
  82. Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Jul;48(1):107-15 - PubMed
  83. Int J Radiat Biol Relat Stud Phys Chem Med. 1972 Apr;21(4):329-42 - PubMed
  84. Free Radic Biol Med. 1995 Jun;18(6):1033-77 - PubMed
  85. Cancer Res. 1994 May 15;54(10):2582-90 - PubMed
  86. Annu Rev Biochem. 1993;62:797-821 - PubMed
  87. Arch Biochem Biophys. 1993 Feb 1;300(2):535-43 - PubMed
  88. Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):649-59 - PubMed
  89. Br J Cancer. 1998 Oct;78(8):993-1003 - PubMed

Publication Types